Long-Term Intravitreal Ranibizumab as a Potential Additional Risk Factor for Neurodegeneration in Parkinson’s Disease: A Case Report
Frontiers in Pharmacology - Switzerland
doi 10.3389/fphar.2018.00608
Full Text
Open PDFAbstract
Available in full text
Categories
Date
June 8, 2018
Authors
Publisher
Frontiers Media SA